Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
This is a single-center, open-label, phase I study to assess the safety and efficacy of the
oral chemotherapy capecitabine in combination with cemiplimab in patients with
hormone-receptor-positive (HR+) metastatic breast cancer.
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute